financetom
Business
financetom
/
Business
/
Soccer-NBA star Durant invests in PSG as French club plan basketball future
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Soccer-NBA star Durant invests in PSG as French club plan basketball future
Jun 20, 2025 11:32 AM

(Reuters) -NBA star Kevin Durant has purchased a minority stake in French soccer club Paris St Germain, the Champions League winners said on Friday, and the Phoenix Suns forward will provide expertise on their planned expansion into basketball.

Durant, two-time NBA champion and four-time Olympic gold medallist, has signed a share purchase and strategic partnership agreement with PSG's majority shareholder Qatar Sports Investments (QSI), through his company Boardroom.

"It is an honour to partner with QSI and to be a shareholder of Paris St Germain, a club and a city that is deeply close to my heart," Durant, who won gold at the Paris Olympics last year, said.

"This club has big plans and I look forward to being part of the next phase of growth and exploring new investment opportunities with QSI."

One of those opportunities is likely to come in the world of basketball, with PSG already involved in early-stage talks with the NBA regarding potential investment and venues for a new basketball league in Europe.

Durant, who had already forged a link with PSG through the club's minority shareholder Arctos Partners, will partner on a wide range of commercial, investment and content production initiatives.

The 36-year-old will also support the club in its strategy of diversification and growth on sporting and commercial fronts, including developing the club's strategy in the United States and other international markets.

PSG said in their release that Durant would provide "expertise on PSG's multi-sport strategy, particularly regarding future projects in the field of basketball".

Durant was recently included in Forbes' 2025 list of the world's highest-paid athletes, coming in at number 10 with earnings of $101.4 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Music streaming firms urge European Commission to reject Apple's proposal in App Store case
Music streaming firms urge European Commission to reject Apple's proposal in App Store case
May 8, 2024
May 8 (Reuters) - A group that represents audio streaming firms including Spotify ( SPOT ) and France's Deezer in Europe has urged the European Commission to reject Apple's ( AAPL ) proposal in a music streaming case. Digital Music Europe expressed concern in a letter submitted to the European Commission on Tuesday that Apple's ( AAPL ) proposal to...
Sector Update: Consumer
Sector Update: Consumer
May 8, 2024
03:24 PM EDT, 05/08/2024 (MT Newswires) -- Consumer stocks were retreating late Wednesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.3% and the Consumer Discretionary Select Sector SPDR Fund (XLY) shedding 0.4%. In corporate news, Shopify ( SHOP ) reported better-than-expected Q1 results amid double-digit gross merchandise volume gains, but it flagged a sales growth slowdown...
Innergex First-Quarter Loss Widens More Than Expected
Innergex First-Quarter Loss Widens More Than Expected
May 8, 2024
04:00 PM EDT, 05/08/2024 (MT Newswires) -- Innergex Renewable Energy ( INGXF ) said Wednesday reported a wider than expected first-quarter loss. The renewable-power company posted a first-quarter loss attributable to owners of C$37.66 million, or C$0.21 per share, in the period, compared to a loss of $12.03 million, or $0.08, a year earlier and wider than the consensus estimate...
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
May 8, 2024
04:02 PM EDT, 05/08/2024 (MT Newswires) -- Cel-Sci ( CVM ) said Wednesday the US Food and Drug Administration indicated in a recent meeting that the company can move forward with a confirmatory registration study of its investigational cancer treatment Multikine. The confirmatory trial needs to enroll 212 subjects and will be conducted in patients with newly diagnosed advanced primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved